A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors

  • Willis, Maurice, (PI)

    Project: Other project

    StatusFinished
    Effective start/end date8/28/178/27/19